Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

HNRNPH1 is required for rhabdomyosarcoma cell growth and survival

ABSTRACT: Rhabdomyosarcoma (RMS) is an aggressive and difficult to treat cancer characterized by a muscle-like phenotype. Although the average 5-year survival rate is 65% for newly diagnosed RMS, the treatment options for metastatic disease are limited in efficacy, with the 5-year survival rate plummeting to 30%. Heterogenous nuclear ribonucleoprotein H1 (HNRNPH1) is an RNA-binding protein that is highly expressed in many cancers, including RMS. To determine the role HNRNPH1 plays in RMS tumorigenesis, we investigated its expression and effect on growth in 3 cellular models of RMS: RD, RH30, and RH41 cells. Upon knockdown of HNRNPH1, growth of all cell lines was dramatically reduced, most likely through a combination of apoptosis and cell cycle arrest. We then recapitulated this finding by performing in vivo xenograft studies, in which knockdown of HNRNPH1 resulted in a striking reduction in tumor formation and growth. We used RNA sequencing to identify changes in gene expression after HNRNPH1 knockdown and found altered splicing of some oncogenes. Our data show that HNRNPH1 may be an important molecular target for the development of future RMS therapy.

ORGANISM(S): Homo sapiens

PROVIDER: GSE104559 | GEO | 2018/02/02

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

miRNA profiling of rhabdomyosarcoma-derived exosomes compared to donor cells, using the Affymetrix GeneChip miRNA 3.0 array

Project description:Exosomes were isolated by differential centrifugation from the fusion negative human embryonal rhabdomyosarcoma (ERMS) cell lines (JR1, Rh36, and RD) and fusion positive alveolar RMS (ARMS) cell lines (Rh30 and Rh41) and characterized by western blot for exosomal markers. miRNA content of the RMS-derived exosomes was determined using the Affymetrix GeneChip miRNA 3.0 array and analyzed to specify differentially deregulated (either enriched or depleted) miRNA relative to cellular miRNA from the respective ERMS and ARMS cell lines. Characterization of the miRNA content of RMS exosome is needed to better understand the mechanism by which these particles exert their physiologic effects, notably on proliferation, migration, invasion, and metastasis.

2016-12-01 | E-MTAB-5321 | biostudies-arrayexpress

Expression data from KDM4 inhibition

Project description:KDM4B shRNA knockdown in Rh30 cells or QC6352 treatment of Rh30 or Rh41 cells We used microarrays to detail the global programme of gene expression underlying cellularisation and identified distinct classes of up-regulated genes during this process.

2022-05-01 | GSE158394 | GEO

miRNA expression profiling in rhabdomyosarcoma cell lines

Project description:Rhabdomyosarcomas (RMS) are rare but very aggressive tumours of childhood that arise as a consequence of regulatory disruption of the growth and differentiation pathways of myogenic precursor cells. Based on morphology, two major RMS subtypes can be identified: embryonal RMS (ERMS) and alveolar (ARMS). To better understand the global function of miRNA in RMS, we analyzed the expression profile of 8 different RMS cell lines (3 PAX3/FOXO1 positive and 5 PAX3/FOXO1 negative RMS) using the mirVana miRNA Probe Set V1 (Ambion). The miRNA microarray platform was able to distinguish PAX3/FOXO1 positive (RH4, RH30, RH28) and negative RMS (RD, CCA, SMS-CTR, RH36, RH18) cell lines through the expression pattern of about 90 miRNAs. Since the translocation positive RMS patients fared worse than the negative counterpart our results demonstrated the potential of miRNA expression profiling to classify different RMS subtypes, in agreement to previous gene expression studies, and set the basis for a further functional characterization of selected miRNAs implicated in RMS pathogenesis and in the different clinical behaviour and aggressiveness of the two RMS subtypes. We decided to study miRNAs with the greatest difference in expression between PAX3/FOXO1 positive and negative RMS:miR-23a, miR-27a and miR-199a.

2015-05-04 | GSE52677 | GEO

RNAseq of rhabdomyosarcoma cells after treatment with SGI-110 and/or Dasatinib

Project description:Patients with metastatic or recurrent rhabdomyosarcoma, the most common childhood soft tissue sarcoma, continue to do poorly and new treatments are needed. In this study we evaluated a novel combination therapy using a dna methyltransferase inhibitor, SGI-110, and the SRC family kinase inhibitor, Dasatinib. To understand the transcriptional changes that occur after treatment with SGI-110 with and without Dasatinib we performed RNAseq on two human RMS cell lines (Rh30 and RD) after 5 days of drug treatment.

2021-04-30 | GSE147240 | GEO

mRNA-seq of PTC-028 treated fusion-positive rhabdomyosarcoma cells

Project description:Purpose: This study aims to identify novel targets in the rare pediatric cancer, fusion-positive rhabdomyosarcoma (FP-RMS), and examine differences/similarities in FP-RMS tumor responses to BMI1 (B lymphoma Mo-MLV insert region 1 homolog) inhibition. Methods: FP-RMS cell lines Rh28 and Rh30 were treated with DMSO (vehicle) or PTC-028, a BMI1 inhibitor, and RNA was collected after 24 or 48 hr in triplicate. RNA-seq was performed, and gene expression data were analyzed through Gene Ontology (GO) and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway analyses. Data from OncoPPi and the STRING database were also utilized in this study. Results: Both Rh28 and Rh30 had some overlapping pathways affected by PTC-028, notably downregulation of cell cycle progression, the DNA damage response, and cholesterol biosynthesis. Rh30+PTC-028 had more genes containing TEAD-motifs downregulated compared to Rh28+PTC-028. Rh28 and Rh30 also had differing changes in expression in kinases of LATS1/2, EPHA2, and PDGFRA. Conclusion: Overall, these results bring new insights into pathways influenced by BMI1 expression and contrasting intertumor drug responses in FP-RMS.

2021-06-11 | GSE176520 | GEO

HNRNPH1 is required for rhabdomyosarcoma cell growth and survival

Project description:HNRNPH1 is required for rhabdomyosarcoma cell growth and survival

| PRJNA413052 | ENA

Expression profiling of the TC32 Ewing sarcoma cell line following silencing of SUPT6H, SF3B1 or HNRNPH1

Project description:The investigation of the function of SUPT6H, SF3B1 and HNRNPH1 in Ewing sarcoma The expression profiles of TC32 Ewing sarcoma cells were determine 48 hours post siRNA-transfected. Groups consisted of untreated cells (three samples), and negative control (siNeg) transfected-TC32 cells (six samples), and TC32 cells in which either SUPT6H, SF3B1 or HNRNPH1 were silenced; three different siRNAs corresponding to each gene were assessed separately.

2016-01-15 | E-GEOD-67736 | biostudies-arrayexpress

Illumina Infinium HumanMethylationEPIC array after SGI-110 treatment in rhabodmyosarcoma cell lines

Project description:Genome wide methylation microarray was performed on two RD and Rh30 rhabdomyosarcoma cell lines treated with 0.5µM of the dna methyltrasferase inhibitor SGI-110 for 5 days or DMSO control.

2021-04-30 | GSE147246 | GEO

Expression profiling of the TC32 Ewing sarcoma cell line following silencing of SUPT6H, SF3B1 or HNRNPH1

Project description:The investigation of the function of SUPT6H, SF3B1 and HNRNPH1 in Ewing sarcoma

2016-01-15 | GSE67736 | GEO

RNA sequencing of C57BL/6J mice, heterozygous for knockout of Hnrnph1 gene, as well as C57BL/6J mice controls

Project description:Previous studies of congenic lines of C57BL/6J-DBA/2J mice compared to C57BL/6 mice revealed a 0.23 QTL for sensitivity to methamphetamine on chromosome 11, which contains two protein coding genes, Rufy1 and Hnrnph1. Subsequent transcription activator-like effector nucleases (TALENs)-mediated introduction of frameshift deletions in the first coding exon of one copy of Hnrnph1 of C57BL/6J mice, revealed comparable association to phenotype. Analysis of the transcriptome and splicesome between these Hnrnph1 heterozygous knockouts and C57BL/6J mice revealed genome-wide differentially expression and exon usage of more than 1000 genes in either.

2017-02-01 | GSE76929 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data